



May 29, 2025

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.
Ref:- Scrip Code:- 500126

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400051
Ref:- Symbol:- PGHL

Dear Sir / Madam,

Sub:- Press release for Audited Financial Results for Financial Year ended March 31,2025

We are enclosing herewith the Press Release, regarding the Audited Financial Results for Financial Year ended March 31,2025, approved at a meeting of the Board of Directors of the Company held today.

Kindly take the same on record.

Thanking you.
Yours faithfully,

For Procter & Gamble Health Limited

Zeal Rupani
Company Secretary



Procter & Gamble Health Limited announces results for Third Quarter and Fiscal Year end results

PAT up 31% for the quarter ended March 31, 2025

Effective this year, the Company has changed its Financial Year from July 1 – June 30 to April 1 – March 31. Accordingly, the current Financial Year of the Company ended on March 31, 2025, covering a period of 9 months from July 1, 2024, to March 31, 2025 (“hereafter referred as “Financial Year 2024-25”)

Mumbai, May 29, 2025: Procter & Gamble Health Limited today announced its financial results for the Third Quarter and Financial Year ended March 31, 2025. The third quarter reported sales of ₹304 crores, up 23% versus the comparable period previous year, and PAT of ₹61 crore, up 31% versus comparable period a year ago, owing to superior brand building activities and supported by strengthened supply chain and go-to-market capabilities.

Considering that the company, effective this year, changed its Financial Year from July 1 – June 30 to April 1 – March 31, the current Financial Year of the Company covers a period of 9 months, from July 1, 2024, to March 31, 2025. The company performance has therefore been indexed versus the comparable 9-month period in the last year (July 1, 2023, to March 31, 2024).

For the nine-month fiscal year ended March 31, 2025, the company recorded sales of ₹918 crores, up 8% vs. the comparable nine-month period a year ago. For the nine-month fiscal, the reported Profit After Tax (PAT) was ₹ 234 crores, up 27% vs. the comparable nine-month period a year ago. Excluding one-time items, this is up 14% versus the comparable nine-month period a year ago.

Commenting on the results, **Mr. Milind Thatte, Managing Director, P&G Health India**, said, *“This was a period of purposeful transformation and acceleration. We invested in initiatives to address the changing needs of our consumers and healthcare professionals, while strengthening our go-to-market and supply chain capabilities. Our strategy - centered on a focused product portfolio, superiority, productivity, constructive disruption, and an agile and accountable organization structure, helped us build a strong foundation for long-term growth. This integrated strategy continues to guide our efforts to generate sustainable, balanced top- and bottom-line growth, along with value creation for our consumers, customers, and shareholders alike”*

The Board of Directors has recommended a final dividend of ₹45 per Equity Share, for the Financial Year ending March 31, 2025, subject to the approval of the shareholders of the company at the ensuing 58th Annual General Meeting. Considering the interim dividend of ₹80 per share, the total dividend payout for the fiscal will be ₹125 per share.

About Procter & Gamble Health Limited: Procter & Gamble Health Limited is one of India’s largest VMS companies manufacturing and marketing vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life, including Neurobion, Livogen, SevenSeas, Evion, Polybion and Nasivion. Please visit www.pghealthindia.com for the latest news and information about Procter & Gamble Health Limited and its brands.

About Procter & Gamble: P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Ambi Pur®, Ariel®, Gillette®, Head & Shoulders®, Olay®, Oral-B®, Pampers®, Pantene®, Tide®, Vicks®, and Whisper®. P&G operates in approximately 70 countries worldwide.

CONTACTS

Media Contacts - Procter & Gamble Health Limited:

Paromita Kundu | kundu.p.1@pg.com

Agency Contact – SPAG FINN Partners

Desiree Crasto | desiree.crasto@finnpartners.com

Jyotsana Saluja | jyotsana.saluja@finnpartners.com